10 results
424B3
SLGL
Sol-Gel Technologies Ltd.
19 Aug 24
Prospectus supplement
6:03am
on an exclusive license agreements for Twyneo® and Epsolay® for the Canadian market, over a fifteen-year term that is renewable for subsequent five-year periods
6-K/A
EX-99.2
SLGL
Sol-Gel Technologies Ltd.
19 Aug 24
Sol-Gel Reports Second Quarter 2024 Financial
6:01am
pharmaceutical company, signed on an exclusive license agreements for Twyneo® and Epsolay® for the Canadian market, over a fifteen-year term that is renewable
6-K
EX-99.2
SLGL
Sol-Gel Technologies Ltd.
16 Aug 24
Sol-Gel Reports Second Quarter 2024 Financial
7:15am
pharmaceutical company, signed on an exclusive license agreements for Twyneo® and Epsolay® for the Canadian market, over a fifteen-year term that is renewable
424B3
SLGL
Sol-Gel Technologies Ltd.
4 Apr 24
Prospectus supplement
9:05am
for Twyneo and Epsolay in Canada, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight will be responsible for obtaining
POS AM
SLGL
Sol-Gel Technologies Ltd.
20 Mar 24
Prospectus update (post-effective amendment)
4:05pm
commercial activities for Twyneo and Epsolay in Canada, over a fifteen-year term that is renewable for subsequent five-year periods. Searchlight
424B3
8e56d9
10 Aug 23
Prospectus supplement
7:20am
6-K
EX-99.2
10mulzghrzfn2
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.1
98njm
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.1
n5n zp5ts01y
6 Jun 23
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to
7:15am
- Prev
- 1
- Next